Blood flow failure as a major determinant in the antitumor action of flavone acetic acid

Journal of the National Cancer Institute

Volumn 81, Issue 13, 1989, Pages 1005-1013

  Zwi, L Jonathan ^a   Baguley, Bruce C ^a   Gavin, John B ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MITOFLAXONE;

ANIMAL EXPERIMENT; BLOOD FLOW; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMAL; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; FLAVONES; ISCHEMIA; MICE; NEOPLASMS, EXPERIMENTAL; ORGANOIDS; REGIONAL BLOOD FLOW; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0024335180     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/81.13.1005     Document Type: Article

References (41)

1. KERR DJ, KAYE SB, CASSTOY J, ET AL: Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 47:6776-6781, 1987
2. PLOWMAN J, NARAYANAN VL, DYKES D, ET AL: Flavone acetic acid: A novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70.631-635, 1986
3. PRATES G, MANZOTTI C, DAMIA G, ET AL: Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347512). Br J Cancer 58:144-146, 1988
4. FINLAY GJ, SMITH GP, FRAY LM, ET AL: Effect of flavone acetic acid on Lewis lung carcinoma: Evidence for an indirect effect J Natl Cancer Inst 80.241-245, 1988
5. BmBY MC, DOUBLE JA, LOADMAN PM: Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512). Br J Cancer 58:341-344, 1988
6. GiAVAZH R, GAROFALO A, DAMIA G, ET AL: Response to flavones acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. Br J Cancer 57:277-280, 1988
7. SMITH GP, CALVELEY SB, SMITH MJ, ET AL: Flavone acetic acid (NSC347512) induces haemorrhagic necrosis of mouse Colon 26 and 38 tumours. Eur J Cancer Clin Oncol 23:1209-1211, 1987
8. BAGULEY BC, CALVELEY SB, CROWE KK, ET AL: Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on Colon 38 tumours in mice. Eur J Cancer Clin Oncol 25:263-269, 1989
9. CUMMINGS J, SMYTH JF, DOUBLE JA, ET AU Identification and characterization of the major human metabolites of flavone acetic acid (FAA). Proc Am Assoc Cancer Res 79:486, 1988
10. CHABOT G, RUTKOWSH KJ Activation of flavone-8-acetic acid to cytotoxic metabolities in vitro. Proc Am Assoc Cancer Res 29:484, 1988
11. CHING L-M, BAGULEY BC: Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347512). Eur J Cancer Clin Oncol 23:1047-1050, 1987
12. HORNUNG RL, YOUNG HA, URBA WJ, ET AL: Immunomodulation of natural killer cell activity by flavone acetic acid: Occurrence via induction of interferon a//3. J Natl Cancer Inst 80:1226-1231, 1988
13. BIBBY MC, DOUBLE JA, LOADMAN PM, ET AC Reduction of tumor blood flow by flavone acetic acid: A possible component of therapy. J Natl Cancer Inst 81:216-220, 1989
14. EVELHOCH JL, BISSERY M-C, CHABOT GG, ET AL: Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 48:4749-4755, 1988
15. TROTTER MJ, CHAPUN DJ, OLIVE PL: The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys 16:531-934, 1989
16. OUVE PL, DURAND RE: Characterization of a carbocyanine derivative as a fluorescent penetration probe. Cytometry 8:571-575, 1987
17. REINHOLD HS, VAN DEN BERO-BLOK AE: Circulation physiology of tumors. In Rodent Tumor Models in Experimental Cancer Therapy (Kallman RF, ed). Elmsford, NY: Pergamon Press, 1987, pp 39-42
18. BROWN JM, YU NY, WORKMAN P: Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours. Br J Cancer 39:310-320, 1979
19. SUTHERLAND RM, DURAND RE: Radiation response of multicell spheroids—an in vitro tumour modeL Curr Top Radiat Res Q 11:87-139, 1976
20. LORD EM: Comparison of in situ and peripheral host immunity to syngeneic tumours employing the multicellular spheroid model. Br J Cancer 41(suppl 4):123-127, 1980
21. REINHOLD HS, VISSER JWM: In vivo fluorescence of endothelial cell nuclei stained with the dye Bis-benzamide H 33342. Int J Microcirc Clin Exp 2:143-146, 1983
22. CHAPLIN DJ, OUVE PL, DURAND RE: Intermittent blood flow in a murine tumor Radiobiological effects. Cancer Res 47:597-601, 1987
23. MURRAY JC, RANDHAWA VS: Misonidazole reduces blood flow in two experimental murine tumours. Br J Cancer 58:128-132, 1988
24. MURRAY JC, RANDHAWA V, DENEKAMP J: The effects of melphalan and misonidazole on the vasculature of a murine sarcoma. Br J Cancer 55:233-238, 1987
25. SMITH KA, HILL SA, BEGG AC, ET AL: Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 57:247-253, 1988
26. CHING L-M, BAGULEY BC: Reduction of cytotoxic effector cell activity in Colon 38 tumours following treatment with flavone acetic acid. Eur J Cancer Clin Oncol, 1989. In press
27. DENEKAMP J, HILL SA, HOBSON B: Vascular occlusion and tumour cell death. Eur J CanceT Clin Oncol 19:271-275, 1983
28. BISSERY M-C, VALERIOTE FA, CHABOT GG, ET AL: Flavone acetic acid (NSC 347512)-induced DNA damage in Glasgow osteogenic sarcoma in vivo. Cancer Res 48:1279-1285, 1988
29. WILTROUT RH, HORNUNG RL: Natural products as antitumor agents: Direct versus indirect mechanisms of activity of flavonoids. J Natl Cancer Inst 80220-222, 1988
30. CHING L-M, BAGULEY BC: Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). Eur J Cancer Clin Oncol 24:1521-1525, 1988
31. SHIMOMURA K, MANDA T, MUKUMOTO S, ET AL: Recombinant human tumor necrosis factor-a: Thrombus formation is a cause of anti-tumor activity. Int J Cancer 41543-247, 1988
32. TRACEY KJ, BEUTLEK B, LOWRY SF: Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474, 1986
33. GULUNO PM, CLARK SH, GRANTHAM FH: The interstitial fluid of solid tumors. Cancer Res 24:780-797, 1964
34. MATTSSON J, PETERSON H-t Influence of vasoactive drugs on tumour blood flow. Anticancer Res 1:59-61, 1981
35. MAJNO G, SHEA SM, LEVENTHAL MS: Endothelial contraction induced by histamine type mediators. J Cell Biol 42:647-672, 1969
36. MANDA T, NISWGAKI F, MORI J, ET AL: Important role of serotonin in the antitumor effects of recombinant human rumor necrosis factor-α in mice. Cancer Res 48:4250-4255, 1988
37. DENEKAMP J: Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45:136-139, 1982
38. JKTLE RL: Chemical modification of tumour blood flow. Int J Hyper-thermia 4:355-371, 1988
39. STRATFORD LI, ADAMS GE, GODDEN J, ET AL: Potentiation of the anti tumour effect of melphalan by the vasoactive agent, hydralazine. Br JCancer 58:122-127, 1988
40. BRAUNSCHWEIGER PG: Effect of cyclophosphamide on the pathophysiniology of RTP-1 solid tumors. Cancer Res 48:4206-4210, 1988
41. KUMMERMEHR J, BUSCHMANN J: The growth of viable cells injected into sterilized tumors. In Rodent Tumor Models in Experimental Cancer Therapy (Kallman RF, ed). Elmsford, NY: Pergamon Press, 1987, pp 101-102